U.S. patent application number 17/019775 was filed with the patent office on 2021-05-06 for method for isolating nucleic acids.
The applicant listed for this patent is QIAGEN GmbH. Invention is credited to Thorsten Voss.
Application Number | 20210130872 17/019775 |
Document ID | / |
Family ID | 1000005331467 |
Filed Date | 2021-05-06 |
![](/patent/app/20210130872/US20210130872A1-20210506\US20210130872A1-2021050)
United States Patent
Application |
20210130872 |
Kind Code |
A1 |
Voss; Thorsten |
May 6, 2021 |
METHOD FOR ISOLATING NUCLEIC ACIDS
Abstract
The present invention pertains to a method for isolating nucleic
acids from a sample, preferably a blood sample, comprising the
following steps: a) obtaining a sample which has been stabilised by
the use of at least one cationic detergent, wherein the cationic
detergent has formed complexes with the nucleic acids; b) obtaining
the complexes optionally together with other sample components from
the stabilised sample, wherein said complexes comprise the nucleic
acids to be isolated; c) resuspending the complexes and optionally
adding one or more additives before, during and/or after
resuspension, thereby obtaining a resuspended sample comprising at
least i) the nucleic acid to be isolated; ii) at least one
chaotropic agent; and iii) at least one chelating agent; and d)
isolating nucleic acids from the resuspended sample. It was found
that adding a chelating agent during resuspension considerably
increases the nucleic acid yield as the formation of precipitates
which irreversibly adhere to the container wall is considerably
reduced.
Inventors: |
Voss; Thorsten; (Hilden,
DE) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
QIAGEN GmbH |
Hilden |
|
DE |
|
|
Family ID: |
1000005331467 |
Appl. No.: |
17/019775 |
Filed: |
September 14, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15596275 |
May 16, 2017 |
10808276 |
|
|
17019775 |
|
|
|
|
14238625 |
Feb 12, 2014 |
9695465 |
|
|
PCT/EP2012/065819 |
Aug 13, 2012 |
|
|
|
15596275 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12Q 1/6806 20130101;
C12N 15/1003 20130101 |
International
Class: |
C12Q 1/6806 20060101
C12Q001/6806; C12N 15/10 20060101 C12N015/10 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 12, 2011 |
EP |
11177426.1 |
Claims
1. A method for isolating nucleic acids from a sample, preferably a
blood sample, comprising the following steps: a) obtaining a sample
which has been stabilised by the use of at least one cationic
detergent, wherein the cationic detergent has formed complexes with
the nucleic acids; b) obtaining the complexes optionally together
with other sample components from the stabilised sample, wherein
said complexes comprise the nucleic acids to be isolated; c)
resuspending the complexes and optionally adding one or more
additives before, during and/or after resuspension, thereby
obtaining a resuspended sample comprising at least i) the nucleic
acid to be isolated; ii) at least one chaotropic agent; and iii) at
least one chelating agent; and d) isolating nucleic acids from the
resuspended sample.
2. The method according to claim 1, wherein the resuspended sample
is put on hold between step c) and step d) for at least 0.2 h, at
least 0.3 h, at least 0.4 h, at least 0.5 h, at least 0.75 h or at
least 1 h and/or for a time period of 0.5 h to 12 h, 1 h to 10 h,
1.5 h to 8 h, 2 h to 7 h or 3 h to 6 h.
3. The method according to claim 1, wherein the resuspension
performed in step c) has one or more of the following
characteristics: a) a resuspension solution is added wherein said
resuspension solution comprises a non-chaotropic salt, preferably
an ammonium salt; b) the chelating agent is added prior, during or
after resuspension; c) the chelating agent is added separately from
the resuspension solution; d) the chelating agent is comprised in a
resuspension solution; e) the chelating agent is added in a
concentration so that the resuspended sample comprises the
chelating agent in a concentration selected from 0.5 mM to 75 mM, 1
mM to 50 mM, 2.5 mM to 25 mM and 5 to 15 mM; f) the chelating agent
is selected from the group consisting of
diethylenetriaminepentaacetic acid (DTPA),
ethylenedinitrilotetraacetic acid (EDTA), ethylene glycol
tetraacetic acid (EGTA) and N,N-bis(carboxymethyl)glycine (NTA)
and/or g) at least one additive is added before, during and/or
after resuspension which is selected from the group consisting of
chaotropic agents, protein-degrading compounds and buffering agents
and thereby is comprised in the resuspended sample.
4. The method according to claim 1, wherein the chelating agent
present in the resuspended sample a) reduces binding of the
precipitated sample to the container comprising the sample; b)
increases the yield of the isolated nucleic acid; and/or c) reduces
variations in the nucleic acid isolation efficiency or quantity
attributable to different holding times between step c) and d).
5. The method according to claim 1, wherein said method has with
respect to the chaotropic agent comprised in the resuspended sample
one or more of the following characteristics: a) the concentration
of the chaotropic agent in the resuspended sample is selected from
the group consisting of 0.1 M to 4 M, 0.5 M to 3 M and 0.75 M to
2.5 M and preferably is at least 1 M; b) the chaotropic agent is
added in step c) in form of a separate solution; c) the chaotropic
agent is added in step c) after resuspension of the complexes and
thereby is comprised in the resuspended sample; and/or d) the
chaotropic agent present in step c) is selected from the group
consisting of chaotropic salts, guanidinium hydrochloride,
guanidinium thiocyanate, guanidinium isothiocyanate, sodium
thiocyanate, sodium iodide, sodium perchlorate, sodium
trichloroacetate, sodium trifluroacetate, urea and preferably is
GTC or GITC.
6. The method according to claim 1, wherein a protein degrading
compound is added in step c).
7. The method according to claim 6, wherein said method has with
respect to the protein degrading compound that is added in step c)
one or more of the following characteristics: a) the protein
degrading compound is a proteolytic enzyme; and/or b) the protein
degrading compound is a proteolytic enzyme selected from the group
consisting of proteinases, proteases, subtilisins and subtilases,
and preferably is proteinase K.
8. The method according to claim 1, wherein step c) comprises aa) a
resuspension solution is added which comprises a non-chaotropic
salt and a chelating agent and which does not comprise a chaotropic
agent and the complexes are resuspended, bb) a chaotropic agent is
added after resuspension of the complexes and thereby becomes
comprised in the resuspended sample wherein preferably, the
chaotropic agent is added to the resuspended complexes in form of
an aqueous solution, cc) optionally a proteolytic enzyme is added
after resuspension of the complexes and thereby is included in the
resuspended sample.
9. The method according to claim 1, wherein the isolation performed
in step d) comprises the following steps: i) digesting and/or
denaturing the resuspended sample, preferably by heating and/or
agitating the resuspended sample in the presence of a proteolytic
enzyme; ii) binding the nucleic acids to a solid phase using
appropriate binding conditions, and iii) optionally washing the
nucleic acids; iv) optionally eluting the nucleic acids.
10. The method according to claim 1, wherein the sample is a blood
sample and in step a) the blood sample is stabilised by contacting
the blood sample with a stabilizing composition comprising i) a
cationic compound of the general formula:
Y.sup.+R.sub.1R.sub.2R.sub.3R.sub.4X.sup.- wherein Y represents
nitrogen or phosphor, preferably nitrogen R.sub.1R.sub.2R.sub.3 and
R.sub.4 independently, represent a branched or unbranched
C.sub.1-C.sub.20-alkyl group, a C.sub.6-C.sub.20-aryl group and/or
a C.sub.6-C.sub.26 aralkyl group; X.sup.- represents an anion of an
inorganic or organic, mono- or polybasic acid; and ii) at least one
proton donor.
11. The method according to claim 1, wherein the sample is a blood
sample and in step a) the blood sample is stabilised by contacting
the blood sample with a stabilizing composition comprising (i) an
amino surfactant having the following formula (2): R1R2R3N(O)x (2)
wherein, R1 and R2 each independently is H, C1-C6 alkyl residue,
C6-C12 aryl residue or C6-C12 aralkyl residue, R3 is C1-C20 alkyl
group, C6-C26 aryl residue or C6-C26 aralkyl residue, X is an
integer of 0 and 1 and (ii) an acid or acid salt.
12. A method according to claim 1, wherein a plurality of samples
is processed and wherein the holding time between step c) and step
d) differs at least between some of the resuspended samples.
13. The method according to claim 1, having one or more of the
following characteristics: a) the nucleic acid is RNA; b) a
plurality of samples is prepared according to steps a) to c)
thereby providing a plurality of resuspended samples, wherein the
resuspended samples are divided into batches and the nucleic acids
are isolated from the batches according to step d) and wherein the
holding time between step c) and d) varies at least between two
batches; c) step d) is performed using an automated system; d)
wherein a plurality of samples is processed manually up to step c)
thereby providing a plurality of resuspended samples and wherein
preferably the resuspended samples are processed using an automated
system for isolating the nucleic acids in step d); and/or e) at
least RNA is isolated from a sample comprising at least RNA and DNA
and wherein isolation step d) comprises the following steps
obtaining the resuspended sample comprising a proteolytic enzyme
and continuing the digestion of the resuspended sample preferably
by incubating the resuspended sample for at least 5 min above room
temperature preferably above 50.degree. C.; removing at least a
portion of the DNA from the resuspended and digested sample, by
binding DNA to a first solid phase and separating the DNA bound to
said first solid phase from the remaining sample comprising the
RNA, binding the RNA to a second solid phase, wherein at least one
chaotropic agent and at least one alcohol in a concentration>30%
v/v is used during this RNA binding step, optionally performing at
least one washing step for washing the RNA bound to said second
solid phase, and optionally performing a DNase digest and/or a
digest using a proteolytic enzyme, optionally eluting the RNA.
14. A method according to claim 1, for isolating RNA from a blood
sample, comprising the following steps: a) obtaining a sample which
has been stabilised by the use of at least one cationic detergent,
wherein the cationic detergent has formed complexes with the
nucleic acids and wherein preferably, a cationic detergent as
defined in claim 10 or 11 was used for stabilisation; b) obtaining
the complexes optionally together with other sample components from
the stabilised sample, wherein said complexes comprise the nucleic
acids to be isolated; c) resuspending the complexes and optionally
adding one or more additives before, during and/or after
resuspension, wherein step c) comprises: aa) adding a resuspension
solution which comprises a non-chaotropic salt and a chelating
agent wherein the resuspension solution does not comprise a
chaotropic salt and resuspending the complexes, bb) adding a
chaotropic agent after resuspension of the complexes wherein
preferably, the chaotropic agent is added to the resuspended
complexes in form of an aqueous solution, cc) optionally adding a
proteolytic enzyme after resuspension of the complexes, thereby
obtaining a resuspended sample comprising at least i) the nucleic
acid to be isolated; ii) at least one chaotropic agent; and iii) at
least one chelating agent; and iv) optionally a proteolytic enzyme;
and d) isolating RNA from the resuspended sample, wherein
preferably, the RNA is isolated according to the features of claims
13e) and wherein preferably, magnetic silica particles are used as
solid phase for binding the RNA and wherein preferably, an
automated system is used for RNA isolation, and wherein a plurality
of samples is prepared according to steps a) to c) thereby
providing a plurality of resuspended samples, wherein the
resuspended samples are divided into batches and the nucleic acids
are isolated from the batches according to step d) and wherein the
holding time between step c) and d) varies at least between two
batches.
15. A method for isolating nucleic acids from a sample, preferably
a blood sample, wherein the nucleic acids are isolated from a
plurality of samples and wherein variations in yield and quality of
the nucleic acids that are isolated from said plurality of samples
which result from that the plurality of samples prepared for
isolation have diverging holding times before the nucleic acids are
isolated from the prepared samples are thereby reduced that the
samples prepared for isolation comprise at least one chaotropic
agent and at least one chelating agent.
16. The method according to claim 15, wherein the nucleic acids are
isolated according to a method that comprises the following steps:
a) obtaining a sample which has been stabilised by the use of at
least one cationic detergent, wherein the cationic detergent has
formed complexes with the nucleic acids; b) obtaining the complexes
optionally together with other sample components from the
stabilised sample, wherein said complexes comprise the nucleic
acids to be isolated; c) resuspending the complexes and optionally
adding one or more additives before during and/or after
resuspension, thereby obtaining a resuspended sample comprising at
least i) the nucleic acid to be isolated; ii) at least one
chaotropic agent; and iii) at least one chelating agent; and d)
isolating nucleic adds from the resuspended sample.
17. Use of a chelating agent in order to prevent or reduce the
formation of a precipitate that attaches to the container wall of a
sample comprising at least one chaotropic agent and nucleic
acids.
18. The use according to claim 17, wherein the sample comprises at
least one ingredient selected from the group of a cationic
detergent, a protein-degrading compound, a salt and/or a buffer.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application is a continuation application of
U.S. application Ser. No. 15/596,275 filed May 16, 2017, which is a
continuation application of U.S. application Ser. No. 14/238,625
filed Feb. 12, 2014, now issued as U.S. Pat. No. 9,695,465, which
is a U.S. national phase application of PCT/EP2012/065819 filed
Aug. 13, 2012, which claims priority to EP Application No.
11177426.1 filed Aug. 12, 2011. U.S. application Ser. Nos.
15/596,275 and 14/238,625 are herein incorporated by reference in
its entity.
[0002] The work leading to this invention has received funding from
the European Community's Seventh Framework Programme
(FP7/2007-2013) under grant agreement n.degree. 222916.
FIELD OF THE INVENTION
[0003] The present invention pertains to the field of isolating
nucleic acids, in particular the isolation of RNA, from biological
samples, in particular from a blood sample, with high yield and
integrity.
BACKGROUND OF THE INVENTION
[0004] Several methods for isolating nucleic acids such as RNA
and/or DNA are known in the prior art that are based on different
principles. Examples of common nucleic acid isolation methods
include but are not limited to extraction, solid-phase extraction,
phenol-chloroform extraction, chromatography, precipitation and
combinations thereof. Very common are nucleic acid isolation
methods which involve the use of chaotropic agents and/or alcohol
in order to bind the nucleic acids to a solid phase, e.g. a solid
phase comprising or consisting of silica. The isolation of RNA is
particularly challenging, because RNAses are omnipresent in rather
high amounts and are active over a broad temperature range and
usually do not need co-factors for their activity. Therefore, it is
a challenge to provide a RNA isolation method which provides the
RNA with good yield and quality.
[0005] Furthermore, in many fields such as e.g. the diagnostic
field it is desirous or even mandatory to isolate the nucleic acids
from a large number of samples. For this purpose it is common to
use automated processes (wherein e.g. many samples are processed at
the same time). To assist the user and to reduce hands-on-time,
robotic systems are commonly used that can process a large number
of samples in parallel. Usually, the samples are prepared manually
for nucleic acid isolation and are then entered into the robotic
system. Respective manual preparation steps are e.g. common for
stabilised blood samples. Respective manual steps include e.g. the
centrifugation of the stabilised sample to generate a nucleic acid
containing pellet and the resuspension of the pellet e.g. in a
resuspension buffer (thereby reducing the sample volume). The
respectively resuspended samples are then ready e.g. for sample
digestion and isolation and are placed into the robotic system.
Examples of commercially available robotic systems that operate
according to this or a similar principle include but are not
limited to QIAsymphony (QIAGEN), QIAcube (QIAGEN) and MagnaPure 96
(ROCHE).
[0006] Even though these robotic systems provide remarkable
advantages when processing a large number of samples, they also
have certain limitations. E.g. said robotic systems can usually
only process a certain number of samples at one time. Said number
is often lower than the number of samples that is manually prepared
as one batch for nucleic acid isolation. Thus, not all of the
prepared samples can be processed at the same time. This has the
effect that the samples prepared for nucleic acid isolation often
have different holding times between their preparation for nucleic
acid isolation (e.g. the centrifugation and resuspension of the
pellet as described above) and the actual nucleic acid isolation.
While the first batch of the prepared samples is processed in the
robotic system, the other prepared samples are put on hold. It was
found that variations in the holding time of the prepared sample
can influence the quality of the isolated nucleic acid as well as
the nucleic acid yield. During longer holding times, a portion of
the nucleic acids can form precipitates which irreversible stick to
the container and thus, can not be purified. Furthermore, the
integrity of the nucleic acids, in particular of RNA, can be
corrupted. Thus, the nucleic acid quantity and/or quality of the
second and subsequent batch of the prepared samples that are
processed in the robotic systems are often lower. Hence, a longer
holding time may reduce the quality and/or the quantity of the
isolated nucleic acids. This in particular poses a problem if
complex samples are processed, such as e.g. blood or samples
derived from blood and/or samples that were stabilised using a
specific chemistry. This problem is further aggravated if large
sample volumes (e.g. 1.5 ml and more) are processed. This loss in
yield and/or integrity can pose problems in particular in sensitive
application fields such as e.g. the diagnostic field wherein an
uniform nucleic acid isolation with respect to yield and quantity
is important and hence, variations due to the used nucleic acid
isolation method must be avoided.
[0007] Furthermore, methods that use magnetic beads as solid phase
for binding and isolating the nucleic acids often show a reduced
nucleic acid yield compared to comparable methods that use a
nucleic acid binding membrane instead. Therefore, a loss in nucleic
acid yield due to the precipitate formation has an even stronger
impact on respective methods and system that use magnetic particles
as nucleic acid binding solid phase.
[0008] Hence, there is a need in the state of the art to provide a
nucleic acid isolation protocol which provides comparable high
nucleic acid yields and also a high yield of small nucleic acids,
even if the holding times vary between samples and also during
extended holding times, a high nucleic acid, in particular RNA
integrity.
[0009] Therefore, it is an object of the present invention to
provide an improved method for isolating a nucleic acid, in
particular RNA, from a sample, in particular a blood sample.
Furthermore, it is the object of the present invention to provide a
method that allows the isolation of nucleic acids from a plurality
of samples with a comparable quality and/or quantity, even if the
holding times between the preparation of the samples for isolation
and the actual isolation of the nucleic acids varies.
SUMMARY OF THE INVENTION
[0010] The present invention is based on the surprising finding
that variations in the nucleic acid yield and quality can be
significantly reduced if at least one chaotropic agent and at least
one chelating agent are included in the sample that is prepared for
nucleic acid isolation. It was found that including at least one
chaotropic agent and at least one chelating agent into the sample
prepared for nucleic acid isolation has the advantage that the
quality and yield of the nucleic acids that are isolated from
respectively prepared samples is substantially maintained even if
the prepared samples stand for a prolonged period of time (e.g.
selected from 0.5 h to 12 h, 0.75 h to 11 h, 1 h to 10 h, 1.25 h to
9 h, 1.5 h to 8.5 h, 1.75 h to 8 h, 1.75 h to 7.5 h, 1.25 h to 7
hours, 1.5 h to 6.5 h, 1.75 h to 6 h, 2 h to 5.5 h) before the
nucleic acids are actually isolated from the respectively prepared
samples. This advantage is particularly important when processing a
large number of samples because in this case variations in the
holding time between samples are rather common, in particular when
using an automated system. However, this advantage is also
generally important as it reduces the need to directly isolate the
nucleic acids from the samples that are prepared for nucleic acid
isolation. This provides more flexibility.
[0011] According to a first aspect, the present invention provides
a method for isolating nucleic acids, preferably RNA, from a
sample, preferably a blood sample, comprising the following steps:
[0012] a) obtaining a sample which has been stabilised by the use
of at least one cationic detergent, wherein the cationic detergent
has formed complexes with the nucleic acids; [0013] b) obtaining
the complexes optionally together with other sample components from
the stabilised sample, wherein said complexes comprise the nucleic
acids to be isolated; [0014] c) resuspending the complexes and
optionally adding one or more additives before, during and/or after
resuspension, thereby obtaining a resuspended sample comprising at
least [0015] i) the nucleic acids to be isolated; [0016] ii) at
least one chaotropic agent; and [0017] iii) at least one chelating
agent; and [0018] d) isolating nucleic acids from the resuspended
sample.
[0019] As discussed above, the method according to the present
invention allows to isolate nucleic acids with comparable good
yield and quality from samples, even if the holding time between
step c) and step d) should vary. The addition of the chaotropic
agent preserves the quality of the nucleic acids contained in the
resuspended sample, in particular of RNA. However, adding a
chaotropic agent has the drawback that the nucleic acids
precipitate during longer holding times and furthermore, the
precipitated nucleic acids may irreversibly stick to the walls of
the container which comprises the sample what considerably reduces
the nucleic acid yield. The inventors now surprisingly found that
the incorporation of a chelating agent in the resuspended sample
considerably reduces the formation of precipitates and furthermore,
prevents the adherence of the precipitate to the walls of the
container comprising the resuspended sample which comprises the
chaotropic agent. Thereby, a loss in the nucleic acid yield can be
efficiently reduced. Thus, the teachings of the present invention
allow the efficient isolation of nucleic acids, in particular RNA,
with comparable yield and quality even if the resuspended samples
prepared for nucleic acid isolation as described above are not
directly processed but have different and/or prolonged holding
times.
[0020] According to a second aspect, a method is provided for
isolating nucleic acids from a sample, preferably a blood sample,
wherein the nucleic acids are isolated from a plurality of samples
and wherein variations in yield and quality of the nucleic acids
that are isolated from said plurality of samples which result from
that the plurality of samples prepared for isolation have diverging
holding times before the nucleic acids are isolated from the
prepared samples are thereby reduced that the samples prepared for
isolation comprise at least one chaotropic agent and at least one
chelating agent.
[0021] According to a third aspect, the present invention pertains
to the use of a chelating agent in order to prevent or reduce the
formation of a precipitate that attaches to the container wall of a
sample comprising at least one chaotropic agent and nucleic acids.
As discussed above, prolonged holding times of respective samples
result in the formation of a precipitate, that sticks to the
container wall comprising the chaotropic agent containing sample,
thereby severely reducing the nucleic acid yield. Thus, the
addition of the chelating agent as is taught by the present
invention has the advantageous effect that the formation of a
respective precipitate is reduced or even completely prevented.
Thus, nucleic acids can be isolated with good yield and quality,
even if the holding time between the preparation of the samples for
isolation and the actual isolation is increased. This provides
particular advantages if the technology of the present invention is
used in order to isolate nucleic acids in automated processes
wherein a large number of samples is prepared for nucleic acid
isolation but wherein only a portion of the prepared samples can be
processed batchwise on the automated system. Thus, the teachings of
the present invention ensure substantially uniform isolation
results with respect to quality and yield even if the holding time
between different samples varies and/or is prolonged, what is in
particular advantageous for challenging fields such as the
isolation of nucleic acids for the medical and/or diagnostic
field.
[0022] Other objects, features, advantages and aspects of the
present application will become apparent to those skilled in the
art from the following description and appended claims. It should
be understood, however, that the following description, appended
claims, and specific examples, while indicating preferred
embodiments of the application, are given by way of illustration
only. Various changes and modifications within the spirit and scope
of the disclosed invention will become readily apparent to those
skilled in the art from reading the following.
BRIEF DESCRIPTION OF DRAWINGS
[0023] FIG. 1 is a graph showing RIN values (RNA integrity number)
of RNA isolated from blood samples as described in Example 1.
[0024] FIG. 2 is a graph showing yield of nucleic acids isolated
from blood samples as described in Example 2.
[0025] FIG. 3 shows the effects of resuspension steps on
precipitate formation at the bottom of test tubes as described in
Example 3.
[0026] FIG. 4 is a graph showing yields of nucleic acids isolated
from blood samples as described in Example 3.
[0027] FIG. 5 is a graph showing RIN values of RNA isolated as
described in Example 3.
[0028] FIG. 6 is a graph showing C.sub.T values obtained with the
MISCRIPT.RTM. primer assay (hsa-miR30b) when analyzing eluates
obtained as described in Example 3.
[0029] FIG. 7 shows the mean yield of total RNA isolated according
to Example 4.
[0030] FIG. 8A shows bulk precipitates stuck at the bottom of test
tubes for samples resuspended without EDTA as described in Example
5.
[0031] FIG. 8B shows no precipitates at the bottom of test tubes
for samples resuspended with EDTA as described in Example 5.
DETAILED DESCRIPTION OF THE INVENTION
[0032] The present invention is based on the finding that
differences in nucleic acid quality and yield that are attributable
to different holding times between sample preparation and actual
nucleic acid isolation can be reduced by incorporating at least one
chaotropic agent and at least one chelating agent into the sample
that is prepared for nucleic acid isolation.
[0033] According to a first aspect, the present invention provides
a method for isolating nucleic acids from a sample, preferably a
blood sample, comprising the following steps: [0034] a) obtaining a
sample which has been stabilised by the use of at least one
cationic detergent, wherein the cationic detergent has formed
complexes with the nucleic acid; [0035] b) obtaining the complexes
optionally together with other sample components from the
stabilised sample, wherein said complexes comprise the nucleic acid
to be isolated; [0036] c) resuspending the complexes and optionally
adding one or more additives before, during and/or after
resuspension, thereby obtaining a resuspended sample comprising at
least [0037] i) the nucleic acid to be isolated; [0038] ii) at
least one chaotropic agent; and [0039] iii) at least one chelating
agent; and [0040] d) isolating nucleic acid from the resuspended
sample.
[0041] The individual steps of the method will be explained in
further detail:
[0042] In step a) a sample is obtained which has been stabilised by
the use of at least one cationic detergent. E.g. the sample can be
stabilised by contacting the sample with at least one cationic
detergent. The cationic detergent supports the lysis the cells
contained in the sample and forms complexes with the released
nucleic acid. The nucleic acids are thereby stabilised. The use of
cationic detergents for stabilising a sample, in particular a blood
sample, is described in the prior art (see e.g. EP 1 031 626 and WO
02/00599, herein incorporated by reference) and will be described
in further detail below. Respective stabilised samples can be e.g.
obtained at one facility, e.g. a hospital and shipped to a second
facility, e.g. a laboratory, wherein the samples are further
processed and wherein the nucleic acids are isolated from the
stabilised sample.
[0043] In step b) the complexes are obtained from the stabilised
sample. Said complexes comprise the nucleic acid to be isolated.
Said complexes also comprise the cationic detergent that was used
for stabilising the sample. Said complexes can be obtained e.g. by
sedimentation or filtration. Thereby, usually other sample
components such as proteins and cell debris are also obtained
together with the nucleic acid containing complexes. Preferably,
the complexes are obtained in form of a pellet. A respective pellet
can be e.g. obtained by centrifuging the sample and discarding the
supernatant thereby obtaining a sample comprising the complexes
comprising the nucleic acids and the cationic detergents. Depending
on the type of sample to be processed, the respective pellet
usually also comprises further sample components such as proteins
and/or cell debris. This is in particular the case when processing
complex samples such as e.g. whole blood or samples derived from
blood such as serum or plasma. Suitable methods for separating the
complexes e.g. by obtaining them in form of a pellet from the
stabilized samples are also described in EP 1 031 626 paragraph
[51] et seq, herein incorporated by reference. Obtaining the
complexes, e.g. in form of a pellet, has the advantage that the
subsequent nucleic acid isolation that is performed in step d) can
be performed in smaller volumina what is cost-efficient as less
reagents are necessary for nucleic acid isolation and furthermore,
provides an important advantage when using automated methods for
nucleic acid isolation because many automated systems are limited
with respect to the volume they can process.
[0044] In step c) the complexes and optional other sample
components, which are preferably obtained in form of a pellet, are
resuspended, thereby obtaining a resuspended sample. Said
resuspended sample comprises the nucleic acid to be isolated, the
cationic detergent and optionally further sample components such as
e.g. proteins and/or cell debris that were collected together with
the complexes. Furthermore, optionally further additives can be
added either before, during or after resuspension such as e.g. a
chaotropic agent and/or a protein degrading compound. Herein, we
refer to the resuspended complexes including optional further
sample components and/or optional additives that were added before,
during and/or after resuspension as "resuspended sample". According
to the invention, the resuspended sample comprises at least one
chaotropic agent. Preferably, the chaotropic agent is added as
separate additive after the complexes were resuspended to provide a
resuspended sample comprising a chaotropic agent. This order is
preferred because the chaotropic agent might hamper the actual
resuspension process of the complexes, in particular if the
complexes are obtained in form of a pellet. Preferably, the
chaotropic agent is added to the resuspended complexes in form of
an aqueous solution as is described below in order to generate a
resuspended sample comprising inter alia the nucleic acids and the
chaotropic agent. As discussed above, the chaotropic agent protects
the nucleic acids, in particular RNA, from degradation, thereby
increasing the quality of the isolated nucleic acids. As is shown
in the examples, if a chaotropic agent is comprised in the
resuspended sample this has the effect that nucleic acids, in
particular RNA, can be obtained with comparable quality even if the
holding time varies and e.g. is extended between step c) and step
d). Therefore, the isolation results obtained for different samples
having different holding times between step c) and step d) are more
uniform and thus comparable when using the method according to the
present invention. However, the chaotropic agent not only has
beneficial effects with respect to the preservation of the nucleic
acid integrity, but also causes problems. During longer holding
times it causes the formation of precipitates that can stick to the
wall (the term "wall" also includes the bottom) of the container
which comprises the resuspended sample. This precipitate formation
and adherence to the container wall that is observed if a
chaotropic agent is included in the resuspended sample reduces the
yield of nucleic acids (DNA and/or RNA) that can be isolated from
the resuspended sample. As is shown by the examples, the yield can
even be reduced by up to 30% or even more, if the resuspended
samples rest for a prolonged holding time between step c) and step
d). This problem is overcome by the teachings of the present
invention by additionally including at least one chelating agent in
the resuspended sample. The chelating agent surprisingly reduces
the formation of insoluble precipitates and also reduces the
adherence of said precipitates to the container wall, thereby
efficiently reducing the loss of nucleic acids during extended
holding times between step c) and step d). The chelating agent can
be added prior, during or after resuspension of the complexes in
order to reduce respectively prevent the formation of precipitates
that reduce the nucleic acid yield. Preferably, the chelating agent
is added prior to the addition of the chaotropic agent. If the
chelating agent is added after resuspension of the complexes, it
should be added basically directly after resuspension in order to
ensure that it can exhibit its beneficial effects described above.
It should be added within one hour, preferably within 30 min, more
preferably within 15 min, more preferably within 10 min, more
preferably within 5 min, most preferably within 3 min.
[0045] Optionally, the method may comprise further treatment steps
in order to prepare the resuspended sample for step d). Examples of
respective additional steps are described in further detail
below.
[0046] In step d), the nucleic acids are isolated from the
resuspended sample. Here, basically any nucleic acid isolation
method can be used. Suitable nucleic acid isolation methods are
known in the prior art and include but are not limited to
extraction, solid-phase extraction, silica-based purification
methods, nucleic acid isolation procedures using chaotropic agents
and/or at least one alcohol and a nucleic acid binding solid phase,
magnetic particle-based purification, phenol-chloroform extraction,
chromatography, anion-exchange chromatography (using anion-exchange
surfaces), electrophoresis, filtration, precipitation, chromatin
immunoprecipitation and combinations thereof. Preferably, the
nucleic acids are isolated in step d) using an automated system.
Preferably, the nucleic acids are isolated from a plurality of
samples. The plurality of samples can be processed batchwise. The
holding time may vary between individual batches, because the
present invention ensures comparable nucleic acid isolation results
even if the holding time significantly varies between batches.
Suitable methods and holding times are also described below.
[0047] The advantages of the respective method were explained above
and are also demonstrated by the examples. A loss in quality and/or
quantity of the isolated nucleic acids that are attributable to
longer holding times between step c) and step d) can be efficiently
avoided due to the modified resuspension step taught by the present
invention. Therefore, the present method provides more flexibility
with respect to the allowable holding times between steps c) and d)
what is in particular beneficial if the method according to the
present invention is performed on an automated system, wherein,
preferably, a plurality of samples are processed in a batchwise
procedure.
[0048] Preferred embodiments of the method according to the present
invention and of the steps a) to d) are described subsequently.
[0049] According to one embodiment, a resuspension solution is
added in step c) to the obtained complexes wherein said
resuspension solution comprises a salt, preferably a non-chaotropic
salt. As salt, several salts can be used including but not being
limited to ammonium salts and alkali metal salts, preferably
ammonium acetate, ammonium sulphate, KCl or NaCl. Preferably, an
ammonium salt is used. Preferably, the chelating agent is comprised
in the resuspension solution. This embodiment is easy in handling
and furthermore, also ensures that the chelating agent can
immediately exhibit it's beneficial effects on the resuspended
sample in that it prevents the formation of precipitates and/or
adherence of the nucleic acids to the container walls when the
resuspended sample when the chaotropic agent is added in order to
protect the nucleic acid. As discussed above, it is preferred to
add the chaotropic agent after the complexes were resuspended and
accordingly, after the resuspension solution was added.
Accordingly, the resuspension solution preferably does not comprise
a chaotropic agent, in particular does not comprise a chaotropic
salt and accordingly, is a non-chaotropic resuspension solution.
According to one embodiment, the resuspension solution comprises
the chelating agent in a concentration of at least 1 mM, at least 5
mM, preferably at least 7.5 mM, more preferred at least 10 mM, at
least 15 mM or at least 20 mM. Preferably, the concentration range
is selected from 1 mM to 150 mM, 5 mM to 100 mM, 5 mM to 75 mM, 7.5
mM to 65 mM, 7.5 mM to 50 mM and 10 mM to 30 mM. As was shown by
examples, already a low concentration of a chelating agent such as
EDTA is sufficient in order to achieve the beneficial effect on the
precipitate formation. In some embodiments to use a lower to medium
concentration of the chelating agent e.g. in a range of 1 mM to 50
mM, preferably 5 mM to 30 mM or 7.5 mM to 20 mM. To use lower
concentrations of the chelating agent reduces the risk that the
chelating agent is carried over into the eluate while still
achieving the beneficial effect on the precipitate formation. The
chelating agent may also be added separately from the resuspension
solution, e.g. in liquid or solid form.
[0050] According to one embodiment, the chelating agent is added in
a concentration so that the resuspended sample comprises the
chelating agent in a concentration of at least 0.5 mM, at least 2.5
mM, preferably at least 3.5 mM, more preferred at least 5 mM, at
least 7.5 mM or at least 10 mM. Preferably, the chelating agent is
added in a concentration so that the resuspended sample comprises
the chelating agent in a concentration selected from 0.5 mM to 100
mM, 2.5 mM to 75 mM, 2.5 mM to 60 mM, 3.5 mM to 50 mM, 3.5 mM to 30
mM, 3.5 mM to 25 mM, 3.5 mM to 20 mM, 5 mM to 15 mM and 5 mM to 10
mM.
[0051] The chelating agent that is used according to the present
invention prevents or reduces the formation of a precipitate and/or
the adherence of precipitate to the container when comprised in the
resuspended sample. According to one embodiment, the chelating
agent is an organic ligand, which is capable of forming two or more
separate coordinate bonds to a metal cation and comprises at least
one nitrogen atom as nucleophilic coordinating atom. According to
one embodiment, the chelating agent is an organic ligand, which is
capable of forming two or more separate coordinate bonds to a metal
cation and comprises at least four nucleophilic coordinating atoms.
According to one embodiment, the chelating agent is an organic
ligand, which is capable of forming two or more separate coordinate
bonds to a metal cation and comprises at least four carboxylic
groups. According to one embodiment, the chelating agent is an
organic ligand, which is capable of forming two or more separate
coordinate bonds to a metal cation, the stability constant of the
resulting complex being at least 10.sup.4 M.sup.-1 in case of
calcium as metal cation. Chelating agents according to the present
invention include, but are not limited to
diethylenetriaminepentaacetic acid (DTPA),
ethylenedinitrilotetraacetic acid (EDTA), ethylene glycol
tetraacetic acid (EGTA) and N,N-bis(carboxymethyl)glycine (NTA).
According to a preferred embodiment, EDTA is used. As used herein,
the term "EDTA" indicates inter alia the EDTA portion of an EDTA
compound such as, for example, K.sub.2EDTA, K.sub.3EDTA or
Na.sub.2EDTA.
[0052] As discussed above, the chelating agent has several
beneficial effects. It reduces the precipitate formation and in
particular the binding of the nucleic acid containing precipitate
to the container comprising the resuspended sample which comprises
a chaotropic agent, thereby reducing or even preventing a loss in
nucleic acid yield, in particular if the resuspended sample stands
for a prolonged times before the nucleic acids are isolated from
the resuspended sample (e.g. more than 0.1 h, more than 0.2 h, more
than 0.3 h, in particular more than 0.5 h, more than 0.75 h, more
than 1 h, more than 1.25 h, more than 1.5 h, more than 1.75 h, more
than 2 h, more than 2.5 h or more than 3 h hours or in a range from
0.1 h to 12 h, 0.5 h to 11 h, 0.75 h to 10 h, 1 h to 9 h, 1.25 h to
8.5 h, 1.5 h to 8 h, 1.75 h to 7.5 h, 1.25 h to 7 hours, 1.5 h to
6.5 h, 1.75 h to 6 h or 2 h to 5.5 h). Thereby, the chelating agent
reduces variations in the nucleic acid isolation efficiency and/or
quantity attributable to different and in particular prolonged
holding times between step c) and d).
[0053] According to one embodiment, the chelating agent that is
used to prevent or reduce the formation of a nucleic acid
containing precipitate and/or the adherence of precipitate to the
container when comprised in the resuspended sample is no classical
buffering agent such as citrate. However, a buffering agent may be
and is also preferably comprised in the resuspended sample in
addition to the chelating agent that is used to prevent or reduce
the formation of the precipitate and/or the adherence of
precipitate to the container. A respective buffering agent may be
e.g. comprised in the resuspension solution.
[0054] As discussed above, in order to preserve the integrity of
the nucleic acids comprised in the sample, in particular RNA, and
in particular during longer holding times of the resuspended
sample, a chaotropic agent is incorporated in and thus comprised in
the resuspended sample. This is particularly advantageous when
isolating RNA which is very sensitive to the omnipresent RNases. As
is demonstrated by the examples, incorporating a chaotropic agent
into the resuspended sample considerably improves the quality of
the isolated RNA, in particular if the sample stands for a longer
time between steps c) and d) as is often the case when isolating
nucleic acids from a plurality of samples using an automated system
and in particular, if a batchwise procedure is used to process the
plurality of samples.
[0055] Any chaotropic agent can be used in step c) that causes
disorder in a protein or nucleic acid by, for example, but not
limited to altering the secondary, tertiary or quaternary structure
of a protein or a nucleic acid while leaving the primary structure
intact. Preferably, a chaotropic salt is used. Preferred chaotropic
agents include but are not limited to chaotropic salts comprising
e.g. thiocyanate, isothiocyanate, perchlorate, trichloroacetate,
trifluoroacetate or iodide and/or comprising guanidinium and are
preferably selected from guanidinium hydrochloride, guanidinium
thiocyanate, guanidinium isothiocyanate, sodium thiocyanate, sodium
iodide, sodium perchlorate, sodium trichloroacetate, sodium
trifluroacetate, urea and the like. Preferably, the chaotropic
agent is GTC or GITC or an equally strong chaotropic agent.
Respective strong chaotropic agents are very efficient in
protecting the nucleic acid, in particular RNA, from degradation.
However, respective strong chaotropic agents strongly induce the
precipitate formation and adherence of the precipitate to the
container wall described above. According to one embodiment, the
resuspended sample comprises the chaotropic agent in a
concentration selected from the group consisting of 0.1 up to the
saturation limit, 0.2 to 6 M, 0.1 M to 4 M, 0.5 M to 3 M, 0.75 M to
2.5 M, most preferred at least 1 M. As is shown in the examples,
using a respective concentration is useful to efficiently preserve
the integrity of the incorporated nucleic acids. The at least one
chaotropic agent may be added in step c) in form of a separate
solution. Said separate solution preferably comprises a chaotropic
salt, e.g. a guanidinium salt, a buffer and/or a chelating agent.
Preferably, said buffer comprises sodium citrate.
[0056] The pH value of the resuspended sample preferably lies in a
range that is selected from 5 to 10, 5.5 to 9.5, 6 to 9, 6.5 to 8.5
and preferably 7 to 8. In a pH range of 5 to 8.5, pellets obtained
from blood samples were particularly well resuspended. Therefore,
according to one embodiment, a resuspension solution is added in
step c) to the complexes, preferably the pellet comprising the
cationic detergent and the nucleic acids that which has a pH value
that achieves, with the added amount, a pH value in the resuspended
sample that lies in the above defined pH range. According to one
embodiment, the pH value of the resuspension solution lies in a pH
range that is selected from 5 to 10.5, 5.5 to 10, 5.7 to 10, 6 to
9.7, 6.3 to 9.5, 6 to 9 and 6 to 8.5. Preferably, the pH range lies
with a range of 5.7 to 10, more preferred 6 to 9. Here, the
achieved nucleic acid yield was optimal.
[0057] According to one embodiment, a protein degrading compound is
added in step c) and thus is comprised in the resuspended sample.
It was found by the inventors that the addition of a protein
degrading compound supports the effects of the chelating agent.
Thus, including a protein degrading compound in the resuspended
sample is beneficial in order to prevent the precipitate formation
and the adherence of nucleic acid containing precipitates to the
container walls. According to a preferred embodiment, the
protein-degrading compound is a proteolytic enzyme. A proteolytic
enzyme refers to an enzyme that catalyzes the cleavage of peptide
bounds, for example in proteins, polypeptides, oligopeptides and
peptides. Exemplary proteolytic enzymes include but are not limited
to proteinases and proteases in particular subtilisins, subtilases,
alkaline serine proteases and the like. Subtilases are a family of
serine proteases, i.e. enzymes with a serine residue in the active
side. Subtilisins are bacterial serine protease that has broad
substrate specificities. Subtilisins are relatively resistant to
denaturation by chaotropic agents, such as urea and guanidine
hydrochloride and anionic detergents such as sodium dodecyl sulfate
(SDS). Exemplary subtilisins include but are not limited to
proteinase K, proteinase R, proteinase T, subtilisin, subtilisin A,
QIAGEN Protease and the like. Discussions of subtilases,
subtilisins, proteinase K and other proteases may be found, among
other places in Genov et al., Int. J. Peptide Protein Res. 45:
391-400, 1995. Preferably, the proteolytic enzyme is proteinase K.
Incorporating a protein-degrading compound such as in particular a
proteolytic enzyme in the resuspended sample has the advantage that
the resuspended sample is also pre-digested during the holding time
before the nucleic acids are isolated in step d). In non-limiting
aspects, the proteolytic enzyme is comprised in the resuspended
sample in a concentration between about 0.05 mg/ml to about 10
mg/ml. In other embodiments the range can be between from about 0.1
mg/ml to about 5 mg/ml, or between about 0.2 mg/ml to about 1.0
mg/ml. It was found by the inventors that the protein-degrading
compound such as in particular a proteolytic enzyme supports the
prevention of precipitate formation and adherence of precipitate to
the container walls. This effect was seen, even if the sample was
not incubated under conditions that are optimal for the performance
of the proteolytic enzyme (e.g. heating and agitation).
[0058] In order to efficiently prepare the resuspended sample for
the nucleic acid isolation in step d) it is preferred to thoroughly
digest the resuspended sample prior to isolating the nucleic acids.
Here, different options exist that may be used in conjunction with
the present invention. Some non-limiting options are subsequently
described.
[0059] According to one embodiment, which is preferred, a
proteolytic enzyme is included in the resuspended sample. As
discussed above, the proteolytic enzyme may be directly added in
step c) either before, during or after, preferably directly after,
resuspension of the complexes and thereby is included in the
resuspended sample. According to one embodiment, the respectively
prepared resuspended sample is then incubated under conditions that
allow at least the partial digestion of the sample. Digestion may
e.g. occur during the holding time of the resuspended sample e.g.
at room temperature. Thereby, the resuspended sample is--depending
on the holding time--at least partially digested prior to step d).
Digestion may be incomplete during the holding time between step c)
and d). In order to ensure an efficient nucleic acid isolation in
step d), a thorough digestion of the resuspended sample is
preferred. Thus, according to one embodiment, after the holding
time of the resuspended sample and thus, preferably in the initial
step of the nucleic acid isolation performed in step d), the
resuspended sample is incubated in step d) under conditions that
support the digestion of the resuspended sample, preferably under
heating and agitation for at least 3 min, preferably at least 5
min. If no proteolytic enzyme has been added in step c), a
proteolytic enzyme would be added in step d) in order to allow an
efficient digestion of the resuspended sample. It is also within
the scope of the present invention to add an additional amount or a
further (e.g. a different) proteolytic enzyme or protein-degrading
compound in step d) even if a proteolytic enzyme was already
included in the resuspended sample in step c).
[0060] According to a preferred embodiment, a proteolytic enzyme is
comprised in the resuspended sample that is obtained in step c).
During the holding time of the resuspended sample, the proteolytic
enzyme can at least partially digest the resuspended sample even
under non-optimal incubation conditions (e.g. at room temperature).
In order to ensure a high efficiency of the digestion, the
resuspended sample is preferably incubated after the holding time
in the initial step of the nucleic acid isolation that is performed
in step d) under conditions that promote the digestion of the
sample, e.g. heating and agitation.
[0061] According to one embodiment, the conditions that allow the
digestion of the sample and which preferably are used in step d)
comprise one or more of the following
[0062] a) heating,
[0063] b) agitation,
[0064] c) the presence of salts,
[0065] d) a pH value of between 6 to 9 and/or
[0066] e) an incubation period of at least 3 min, preferably at
least 5 min, most preferred for at least 10 min.
[0067] Preferably, said incubation step is performed under heating.
Preferably, the resuspended sample is heated at least to a
temperature of 35.degree. C., at least 40.degree. C., or at least
50.degree. C. and preferably is heated to a temperature of at least
55.degree. C. during incubation. Using respective higher
temperatures during incubation is in particularly favourable if a
proteolytic enzyme such as proteinase K is used as
protein-degrading compound that shows its optimal, respective
highest activity at higher temperatures. Under such conditions, the
digestion of the resuspended sample is promoted. Of course, a
temperature should be used wherein the proteolytic enzyme is
active. Furthermore, it is preferred that the said incubation step
is performed while agitating the resuspended sample. Non-limiting
examples of agitation include shaking, stirring, mixing, or
vibrating. In certain aspects, agitation comprises shaking. The
shaking can be one, two, or three dimensional shaking. A variety of
shaking or agitating devices can be used. Non-limiting examples
include the Thermomixer (Eppendorf), TurboMix (Scientific
Industries), Mo Bio Vortex Adapter (Mo Bio Laboratories), Microtube
holder vortex adapter (Troemner), and the Microtube foam rack
vortex attachment (Scientific Industries). Agitating can be
performed for example in a mixer with at least 50 rpm, at least 100
rpm, at least 200 rpm or at least 500 rpm. Preferably, heating and
agitation is simultaneously performed, for example by using a
thermomixer or an equivalent apparatus that allows simultaneous
heating and agitation. When using at least one proteolytic enzyme
as protein-degrading compound, incubation conditions are used that
ensure that said enzyme works efficiently and is catalytically
active. The conditions depend on the proteolytic enzyme used and
are known, respectively determinable by the skilled person.
Preferably, the incubation is performed in the presence of salts
and/or ions that promote and/or maintain the activity of the
proteolytic enzyme. Suitable salts include but are not limited to
NaCl, KCl, MgCl.sub.2, or CaCl.sub.2 or chaotropic agents such as
chaotropic salts.
[0068] The above described conditions are particularly favourable
when using a proteolytic enzyme as protein-degrading compound and
said conditions promote the digestion of the resuspended sample. As
discussed above, a digestion of the resuspended sample under
respective conditions is preferably performed as initial step in
nucleic acid step d).
[0069] Furthermore, as at least one chaotropic agent is included in
the resuspended sample in order to preserve the integrity of the
comprised nucleic acid, in particular the RNA, the digestion is
performed in the presence of at least one chaotropic agent,
preferably a chaotropic salt. It is also within the scope of the
present invention to add a further amount or type of chaotropic
agent at the time wherein the digestion is performed. For this
purpose a digestion solution can be added which comprises at least
one chaotropic agent, which may be the same or different than the
one(s) that is/are included in the resuspended sample. Said
digestion solution may also comprise additional compounds such as
e.g. detergents and salts that promote the digestion and/or
preserve the comprised nucleic acid. Any chaotropic agent can be
used for that purpose that causes disorder in a protein or nucleic
acid by, for example, but not limited to altering the secondary,
tertiary or quaternary structure of a protein or a nucleic acid
while leaving the primary structure intact. Preferred chaotropic
agents that can be used during incubation with the at least one
protein-degrading compound are chaotropic salts which include but
are not limited to guanidinium hydrochloride, guanidinium
thiocyanate, guanidinium isothiocyanate, sodium thiocyanate, sodium
iodide, sodium perchlorate, sodium trichloroacetate, sodium
trifluroacetate, urea and the like.
[0070] The incubation with the at least one protein-degrading
compound to digest the resuspended sample is usually performed at a
pH value that does not lead to a degradation of the comprised
nucleic acid. Furthermore, when using a proteolytic enzyme as
protein-degrading compound, a pH value should be used wherein the
proteolytic enzyme is active. Preferably, the incubation with the
at least one protein-degrading compound for digesting the
resuspended sample is performed at a pH between 4.3 to 9, 6 to 8
and, preferably, is performed at a neutral pH value.
[0071] As discussed above, according to one embodiment, the
proteolytic enzyme is included in the resuspended sample. In this
embodiment, digestion already occurs during the holding time of the
resuspended sample between step c) and d). However, as the
resuspended samples may have different holding times prior to step
d) and furthermore, digestion might not be complete under the
conditions that are present during the holding time, it is
preferred to additionally incubate the resuspended sample after the
holding time under conditions that promote the digestion of the
sample in the initial step of the nucleic acid isolation that is
performed in step d).
[0072] According to a preferred embodiment, the incubation for
digesting the resuspended sample is performed under heating,
agitation, in the presence of chaotropic agents, a pH of 5 to 9,
preferably 6 to 8, preferably a neutral pH, and for an incubation
period of at least 3, preferably at least 5 minutes. In order to
ensure efficient degradation of the proteins in step d), the
resuspended sample should be incubated in step d) for a period of
at least 3 minutes, preferably at least 5 minutes at elevated
temperatures preferably above 50.degree. C. in order to ensure
efficient protein degradation. According to a preferred embodiment,
the incubation is performed for at least 5 minutes, preferably for
at least 10 minutes.
[0073] After optionally, but preferably digesting the resuspended
sample as described above as initial step of the nucleic acid
isolation procedure in step d), the nucleic acid can be e.g. bound
to a solid phase and the nucleic acid can be optionally eluted
therefrom. Preferred embodiments are described below.
[0074] As solid phase, any material that is capable of binding
nucleic acids that are present in or are released from a sample can
be used and include a variety of materials that are capable of
binding nucleic acids under suitable conditions. Exemplary solid
phases that can be used in conjunction with the present invention
include, but are not limited to, compounds comprising silica,
including but not limited to, silica particles, silicon dioxide,
diatomaceous earth, glass, alkylsilica, aluminum silicate, and
borosilicate; nitrocellulose; diazotized paper; hydroxyapatite
(also referred to as hydroxyl apatite); nylon; metal oxides;
zirconia; alumina; polymeric supports, diethylaminoethyl- and
triethylaminoethyl-derivatized supports, hydrophobic chromatography
resins (such as phenyl- or octyl Sepharose) and the like. The term
solid phase is not intended to imply any limitation regarding its
form or design. Thus, the term solid phase encompasses appropriate
materials that are porous or non-porous; permeable or impermeable;
including but not limited to membranes, filters, sheets, particles,
magnetic particles, beads, gels, powders, fibers, and the like.
According to one embodiment, the surface of the solid phase such as
e.g. the silica solid phase is not modified and is, e.g., not
modified with functional groups.
[0075] According to a preferred embodiment, a solid phase
comprising silica is used. Silica based nucleic acid isolation
methods are broadly used in the prior art. The solid phase
comprising silica may e.g. have the form of a filter, fibres,
membrane or particles. In particular preferred is the use of silica
particles that can be used in form of beads and which preferably
have a particle size of about 0.02 to 30 .mu.m, more preferred 0.05
to 15 .mu.m and most preferred of 0.1 to 10 .mu.m. To ease the
processing of the nucleic acid binding solid phase, preferably
magnetic silica particles are used. The magnetic silica particles
may e.g. be ferrimagnetic, ferromagnetic, paramagnetic or
superparamagnetic. Suitable magnetic silica particles are for
example described in WO 01/71732, WO 2004/003231 and WO
2003/004150. Other magnetic silica particles are also known from
the prior art and are e.g. described in WO 98/31840, WO 98/31461,
EP 1 260 595, WO 96/41811 and EP 0 343 934 and also include for
example magnetic silica glass particles.
[0076] According to one embodiment, binding is performed under
conditions having one or more, preferably at least two of the
following characteristics: [0077] a) binding is performed in the
presence of at least one chaotropic agent, [0078] b) binding is
performed in the presence of at least one alcohol, [0079] c)
binding is performed in the presence of at least one detergent,
[0080] d) binding is performed under conditions that promote
binding of the nucleic acids, in particular the RNA, and/or [0081]
e) binding is performed under conditions that promote binding of
small nucleic acids, in particular small RNA species.
[0082] According to one embodiment, the binding of the nucleic
acids to the solid phase is performed in step d) in the presence of
at least one chaotropic agent, preferably a chaotropic salt and/or
in the presence of at least one alcohol. As discussed above, also a
mixture of chaotropic agents can be used. The concentration of the
chaotropic agent or mixture of chaotropic agents that are used
during binding may lie in a range of 0.05 M up to the saturation
limit. Preferred concentration ranges lie, depending on the
chaotropic agent used, within 0.1 M to 7 M, 1 M to 7 M, 1.5 M to 6
M and 2 M to 4 M. Suitable chaotropic agents are in particular
chaotropic salts and include but are not limited to guanidinium
hydrochloride, guanidinium thiocyanate, guanidinium isothiocyanate,
sodium thiocyanate, sodium iodide, sodium perchlorate, sodium
trichloroacetate, sodium trifluoroacetate, urea and the like and in
particular preferred are guanidinium hydrochloride, guanidinium
thiocyanate and guanidinium isothiocyanate. As discussed above, the
resuspended sample already comprises at least one chaotropic agent
that has been added in order to preserve the integrity of the
nucleic acids in the resuspended sample during longer holding times
between step c) and step d). Thus, it is not necessary to
additionally add a chaotropic agent in order to allow binding of
the nucleic acids to the solid phase. However, it is also within
the scope of the present invention to additionally add at least one
chaotropic agent in step d) e.g. in form of an aqueous binding
solution.
[0083] As alcohol that can be used to promote binding, it is
preferred to use short chained branched or unbranched alcohols with
preferably one to 5 carbon atoms. Examples are methanol, ethanol,
propanol, isopropanol and butanol. Also mixtures of alcohol can be
used. The alcohol is preferably selected from isopropanol and
ethanol, particularly well suitable is isopropanol when isolating
RNA as target nucleic acid. Preferably, the method according to the
present invention does not involve the use of phenol and/or
chloroform.
[0084] The alcohol may be comprised in the binding mixture in a
concentration of 10% v/v to 90% v/v, in particular 15% v/v to 80%
v/v, 20% to 80% v/v. The binding mixture in particular comprises
the resuspended sample and the solid phase and may optionally
comprise further agents that were added to establish, respectively
improve the binding conditions. For isolating total RNA which also
comprises small RNA, it is beneficial to use an alcohol
concentration of .gtoreq.30% v/v, preferably .gtoreq.40% v/v to
.ltoreq.90% v/v, more preferred .gtoreq.50% v/v to .ltoreq.90% v/v
or .gtoreq.60% v/v to .ltoreq.80% v/v during binding and thus in
the binding mixture. Respective higher concentrations of alcohol
improve the binding and thus the isolation of short nucleic acids
(usually having a size respectively length of 500 nt or less), in
particular small RNA species. Most preferred is an alcohol
concentration of .gtoreq.40% v/v to .ltoreq.90% v/v or .gtoreq.60%
v/v to .ltoreq.80% v/v during binding when intending to isolate RNA
which includes small RNA. These concentrations work particularly
well if the chaotropic agent(s) is/are present in higher
concentrations and when binding the nucleic acids to a silica
surface.
[0085] Thus, according to one embodiment, the isolation in step d)
is performed using binding conditions having one or more of the
following characteristics to bind the nucleic acids to a solid
phase: [0086] a) an alcohol concentration is used that is selected
from the group consisting of 10% v/v to 90% v/v, 15%v/v to 90% v/v,
20% v/v to 85%v/v, 30%v/v to 80%v/v, 40% v/v to 85% v/v, 40%v/v to
80%, 40% v/v to 70%, .gtoreq.50% v/v to .ltoreq.80% v/v and
.gtoreq.60% v/v to .ltoreq.80% v/v, [0087] b) a concentration of
one or more chaotropic agents is used that is selected from the
group consisting of 0.05 M up to the saturation limit, 0.1 M to 6 M
and 1 M to 4 M, and/or [0088] c) an alcohol concentration of at
least 30% v/v, preferably at least 40% v/v and at least one
chaotropic agent is used for binding RNA, including small RNAs to
the solid phase.
[0089] To establish respective binding conditions, a binding
solution which comprises e.g. the alcohol and the chaotropic agent
can be added e.g. to the resuspended sample, preferably to the
resuspended digested sample.
[0090] Optionally, one or more detergents can be added to the
binding mixture to promote binding of the nucleic acid to the solid
phase. Preferably, at least one ionic and/or at least one non-ionic
detergent is added. Preferably, a non-ionic detergent is used in a
concentration of at least 5%. Said detergent can be added, e.g.,
together with the binding solution or can be provided by the
resuspended sample and/or the digestion solution if a respective
digestion solution is added to promote the digestion, respectively
lysis of the sample.
[0091] Furthermore, a buffer such as a biological buffer can be
used for binding, respectively can be incorporated in the binding
solution. Non-limited examples of biological buffers include but
are not limited to HEPES, MES, MOPS, TRIS, BIS-TRIS Propane and
others. Preferably, a Tris buffer is used in the binding
solution.
[0092] Therefore, according to one embodiment, the nucleic acid
isolation in step d) comprises the addition of a binding solution
which comprises at least one alcohol and/or at least one chaotropic
agent and optionally a biological buffer, preferably Tris, in order
to establish the binding conditions that allow to bind the nucleic
acid that are comprised in the resuspended sample to the solid
phase. Optionally, the binding solution additionally comprises a
detergent as is described above. However, the components can also
be added separately to establish suitable binding conditions in the
binding mixture. Preferably, the binding solution pH is in a range
that includes 8. According to one embodiment, the pH of the binding
solution is in the range from pH 7.0 to 9, preferably 7.5 to 8.5;
most preferred the binding solution has a pH of 8.
[0093] According to one embodiment, one or more washing steps are
performed in isolation step d) in order to further purify the
isolated nucleic acids. According to one embodiment, one or more
washing steps are performed while the nucleic acid is bound to the
solid phase. For this purpose common washing solutions may be used.
According to one embodiment, the solution used for washing
comprises at least one chaotropic agent, at least one alcohol, at
least one detergent and/or at least one buffering component.
Chaotropic agents that can be used in the washing solutions include
but are not limited to guanidinium hydrochloride, guanidinium
thiocyanate, guanidinium isothiocyanate and sodium iodide.
Furthermore, chaotropic salts can be used which comprise a
chaotropic anion selected form the group consisting of
trichloroacetate, perchlorate and trifluoroacetate. Examples of
respective chaotropic salts are alkali salts like sodium
perchlorate, sodium trichloroacetate and sodium trifluoroacetate.
As alcohol, short chained branched or unbranched alcohols with
preferably one to 5 carbon atoms can be used for washing,
respectively in the washing solution. Examples are methanol,
ethanol, propanol, isopropanol and butanol. Preferably, isopropanol
and/or ethanol are used. Preferably, the washing solution comprises
at least 50% alcohol and at least 1 M chaotropic salt, preferably
at least 2 M chaotropic salt. Furthermore, the washing solution may
comprise a detergent. Preferably, ionic and/or non-ionic detergents
are used as detergent. Preferably, a non-ionic detergent is used in
a concentration of at least 5%.
[0094] A further suitable washing solution which can be used
alternatively or also in addition to the washing solutions
described above comprises an alcohol and a biological buffer.
Suitable alcohols and biological buffers are described above.
Preferably, isopropanol or ethanol, most preferred ethanol is used
for this second washing step. Preferably, ethanol is used in a
concentration of at least 70% v/v, preferably at least 80% v/v. The
biological buffer is preferably Tris at a pH of approx. 7 to 8.
According to one embodiment, the solution used for washing
comprises at least one chaotropic agent, at least one alcohol, at
least one detergent and/or at least one buffering component.
[0095] In case it is desired to perform an elution step to elute
the nucleic acids from the solid phase, elution can be performed
for example with classical elution solutions such as water, elution
buffers, in particular biological buffers such as Tris and
preferably elution solutions are used that do not interfere with
the intended downstream application. After elution, the eluate can
be heat denatured. However, it is also within the scope of the
present invention to release and thus elute the nucleic acids from
the solid phase in step c) and/or e) by other elution means such as
e.g. heating.
[0096] According to one embodiment, DNA as well as RNA is bound in
step d) to a solid phase and thus is isolated according to the
method of the present invention. As discussed above, the teachings
of the present invention increase the overall nucleic acid yield
while preserving the integrity of the nucleic acids.
[0097] According to one embodiment, the sample comprises at least
one non-target nucleic acid and at least one target nucleic acid
and the method aims at isolating predominantly the target nucleic
acid. E.g. the non-target nucleic acid can be DNA and the target
nucleic acid can be RNA or vice versa.
[0098] According to one embodiment, isolation step d) comprises
several intermediate steps in order to allow the isolation of
predominantly the target nucleic acid. According to one embodiment,
isolation step d) comprises not only a sample digestion step (see
above) but also an intermediate step that removes at least a
portion of non-target nucleic acid. Preferably, the non-target
nucleic acid is removed by binding at least a portion of the
non-target nucleic acid under appropriate conditions to a solid
phase and then separating the non-target nucleic acid bound to the
solid phase from the remaining sample comprising the target nucleic
acid. This can be achieved e.g. by the addition of a suitable solid
phase under conditions wherein mainly the non-target nucleic acids
are bound to the solid phase. Suitable methods for selectively
removing a non-target nucleic acid from a target nucleic acid are
for example described in EP 0 880 537 and WO 95/21849, herein
incorporated by reference. If desired, said non-target nucleic acid
may also be further used, e.g. further processed such as e.g.
eluted from the solid phase. However, it may also be discarded.
When intending to isolate (only) RNA as target nucleic acid, the
non-target nucleic acid is usually DNA.
[0099] In order to further reduce the amount of non-target nucleic
acids in the isolated target nucleic acid, an intermediate step for
degrading non-target nucleic acids using a suitable enzyme can be
performed after at least the portion of the non-target nucleic acid
was removed. It is also within the scope of the present invention
to skip the removal step and to destroy non-target nucleic acids by
using one or more appropriate enzymes only. Thus, according to one
embodiment, isolation step d) comprises performing an enzymatic
treatment in order to degrade (remaining) non-target nucleic acids.
According to one embodiment wherein RNA is isolated as target
nucleic acid, a DNase treatment is performed. As the conditions for
performing a DNase digest are well known in the prior art, they do
not need further description here. Basically the same applies when
isolating DNA as target nucleic acid and accordingly when using an
RNase for degrading RNA as non-target nucleic acid.
[0100] According to a preferred embodiment of the present invention
wherein RNA is isolated from a sample comprising at least RNA and
DNA, isolation step d) comprises the following steps [0101] i)
removing at least a portion of the DNA from the resuspended and
preferably digested sample, by binding DNA to a first solid phase
and separating the DNA bound to said first solid phase from the
remaining sample comprising the RNA, [0102] ii) binding the RNA to
a second solid phase, wherein at least one chaotropic agent and at
least one alcohol in a concentration .gtoreq.30% v/v is used during
this binding step ii), [0103] optionally performing at least one
washing step for washing the RNA bound to said second solid phase,
and [0104] optionally eluting the RNA from said second solid
phase.
[0105] Isolation step d) may also comprise additional steps, e.g.
at least one additional enzymatic digestion step to digest
remaining DNA and/or protein contaminations.
[0106] According to a preferred embodiment of the present invention
wherein at least RNA is isolated from a sample comprising at least
RNA and DNA, isolation step d) comprises the following steps:
[0107] Obtaining the resuspended sample comprising a proteolytic
enzyme and continuing the digestion of the resuspended sample
preferably by incubating the resuspended sample for at least 5 min
above room temperature preferably above 50.degree. C. Suitable
incubation conditions are described above, it is referred to the
respective disclosure. [0108] Removing at least a portion of the
DNA from the resuspended and digested sample, by binding DNA to a
first solid phase and separating the DNA bound to said first solid
phase from the remaining sample comprising the RNA. Thereby, the
DNA can be removed. The removed DNA can be further processed, e.g.
analysed or amplified. Optionally, the DNA is eluted from the first
solid phase if a parallel isolation of RNA and DNA is of interest.
[0109] Binding the RNA to a second solid phase, wherein at least
one chaotropic agent and at least one alcohol in a concentration
.gtoreq.30% v/v is used during this RNA binding step. Suitable
binding conditions and in particular suitable concentration ranges
for the chaotropic agent and the alcohol are described above, it is
referred to the respective disclosure. [0110] Optionally performing
at least one washing step for washing the RNA bound to said second
solid phase. Details with respect to the washing step were
described above, it is referred to the respective disclosure.
[0111] Optionally performing a DNase digest and/or a digest using a
proteolytic enzyme. Performing a DNase digest has the advantage
that remaining traces of DNA can be efficiently removed. Performing
a second protein digestion step is also advantageous in order to
increase the purity of the isolated RNA. Preferably, the RNA is
eluted prior to performing the DNase digest and the proteolytic
enzyme is added after the DNase digest was performed and the
reaction mixture is incubated in the presence of a chaotropic
agent. Suitable digestion conditions are also described above.
Preferably, proteinase K is used as proteolytic enzyme. Details
with respect to said second protein digestion step and the
associated advantages are described in EP 10 007 346.9. After the
protein digestion step was performed, the RNA is re-bound to the
second solid phase preferably by adding at least one chaotropic
agent and at least one alcohol. Suitable binding conditions are
described above, it is referred to the respective disclosure.
Preferably, the same binding conditions are used that were used in
the first RNA binding step. After rebinding, optionally one or more
washing steps can be performed. Optionally the RNA is eluted from
said second solid phase and optionally the eluted RNA is denatured
by performing a heat treatment.
[0112] It is also within the scope of the present invention to
perform additional intermediate steps than the ones described
herein. However, according to certain embodiments, no additional
steps other than the ones described herein are performed.
[0113] The sample from which the nucleic acids are to be isolated
can be, respectively were according to one embodiment stabilised by
contacting the sample with a stabilizing composition having one or
more of the following characteristics: [0114] a) it comprises
[0115] a) a cationic compound of the general formula:
[0115] Y.sup.+R.sub.1R.sub.2R.sub.3R.sub.4X.sup.- [0116] wherein Y
represents nitrogen or phosphor, preferably nitrogen [0117]
R.sub.1R.sub.2R.sub.3 and R.sub.4 independently, represent a
branched or unbranched C.sub.1--C.sub.20-alkyl group, a
C.sub.6-C.sub.20_aryl group and/or a C.sub.6-C.sub.26 aralkyl
group; [0118] X.sup.- represents an anion of an inorganic or
organic, mono- or polybasic acid; and [0119] b) at least one proton
donor.
[0120] According to one embodiment, which is particularly preferred
when RNA is isolated from a biological sample such as whole blood
or blood products such as plasma or serum, the nucleic acids
contained in the sample are stabilised preferably immediately after
the biological sample has been taken from its natural environment
in order to preserve the status quo of the nucleic acid population
comprised in the sample, in particular the transcription pattern.
This is particularly beneficial in the medical and diagnostic
field.
[0121] Thus, according to one embodiment, after the sample was
obtained it is preferably immediately mixed with a nucleic acid
storage stabilization composition for stabilizing nucleic acids in
said sample prior to isolating the nucleic acids therefrom. E.g.
the sample can be collected in a suitable collection device, e.g.
an evacuated blood collection tube, which comprises the
stabilization composition. Thereby, the sample is immediately
stabilized upon collection. According to one embodiment, said
stabilization composition comprises [0122] a) a cationic compound
of the general formula:
[0122] Y.sup.+R.sub.1R.sub.2R.sub.3R.sub.4X.sup.- [0123] wherein Y
represents nitrogen or phosphor, preferably nitrogen [0124]
R.sub.1R.sub.2R.sub.3 and R.sub.4 independently, represent a
branched or unbranched C.sub.1--C.sub.20-alkyl group, a
C.sub.6--C.sub.20_aryl group and/or a C.sub.6--C.sub.26 aralkyl
group; [0125] X.sup.- represents an anion of an inorganic or
organic, mono- or polybasic acid; and [0126] b) at least one proton
donor, wherein the proton donor is preferably present in the
composition in a concentration of above 50 mM to saturation and
wherein the proton donor is preferably selected from the group
consisting of saturated aliphatic monocarboxylic acids, unsaturated
alkenyl-carboxylic acids, saturated and/or unsaturated aliphatic
C.sub.2--C.sub.6-dicarboxylic acids, aliphatic hydroxyl-di- and
tricarboxylic acids, aliphatic ketocarboxylic acids, amino acids or
the inorganic acids or the salts thereof, on their own or in
combination.
[0127] Preferably, R.sub.1 denotes a higher alkyl group with 12, 14
or 16 carbon atoms and R.sub.2, R.sub.3 and R.sub.4 each represent
a methyl group.
[0128] Preferably, the anion X.sup.- represents an anion of
hydrohalic acids or anions of mono- or dibasic organic acids, most
preferred the anion X.sup.- is selected from the group consisting
of bromide, chloride, phosphate, sulphate, formate, acetate,
propionate, oxalate, malonate, succinate or citrate.
[0129] Preferably, the proton donor is selected from the group
consisting of saturated aliphatic monocarboxylic acids, unsaturated
alkenyl-carboxylic acids, saturated and/or unsaturated aliphatic
C.sub.2-C.sub.6-dicarboxylic acids, aliphatic ketocarboxylic acids,
amino acids or the inorganic acids or the salts thereof, and
combinations thereof. Preferably, the aliphatic monocarboxylic acid
comprises a C.sub.1-C.sub.6-alkyl-carboxylic acid selected from the
group consisting of acetic acid, propionic acid, n-butyric acid,
n-valeric acid, isovaleric acid, ethyl-methyl-acetic acid
(2-methyl-butyric acid), 2,2-dimethylpropionic acid (pivalic acid),
n-hexanoic acid, n-octanoic acid, n-decanoic acid or n-dodecanoic
acid (lauric acid) or mixtures thereof. Preferably, the aliphatic
alkenyl-carboxylic acid is selected from the group consisting of
acrylic acid (propenoic acid), methacrylic acid, crotonic acid,
isocrotonic acid or vinylacetic acid or mixtures thereof.
Preferably, the saturated aliphatic C.sub.2-C.sub.6-dicarboxylic
acid is selected from the group consisting of oxalic acid, malonic
acid, succinic acid, glutaric acid or adipic acid or mixtures
thereof. Most preferred, the aliphatic dicarboxylic acid is oxalic
acid or succinic acid or mixtures thereof. Preferably, the
aliphatic hydroxy-di- and --tricarboxylic acids are selected from
the group consisting of tartronic acid, D-(+), L-(-) or DL-malic
acid, (2R, 3R)-(+)-tartaric acid, (2S, 3S)-(-)-tartaric acid,
meso-tartaric acid and citric acid or mixtures thereof. Most
preferred, the unsaturated dicarboxylic acid is maleic and/or
fumaric acid or mixtures thereof. Preferably, the unsaturated
tricarboxylic acid is aconitic acid. Preferably, the aliphatic
ketodicarboxylic acids are mesoxalic acid or oxaloacetic acid, or
mixtures thereof. Preferably, the amino acids are selected from the
group consisting of aminoacetic acid (glycine),
alpha-aminopropionic acid (alanine), alpha-amino-iso-valeric acid
(valine), alpha-amino-iso-caproic acid (leucine) and
alpha-amino-beta-methylvaleric acid (isoleucine), or mixtures
thereof.
[0130] Preferably, the stabilising composition is present in an
aqueous solution. Preferably, the cationic compound is comprised in
a concentration in the range from 0.01 weight percent to 15 weight
percent.
[0131] Suitable stabilising solutions are also described in detail
e.g. in U.S. Pat. No. 7,270,953, herein incorporated by reference.
As described above, the cationic compound comprised in the
stabilisation composition forms complexes with nucleic acids
comprised in the sample. According to one embodiment, the
stabilised sample does not comprise a chelating agent. According to
another embodiment, it may comprise a chelating agent.
[0132] According to an alternative embodiment, the stabilization
composition comprises a detergent which comprises under the used
conditions a charged quarternary ammonium cation as polar head
group and thus is or becomes cationic under the used stabilisation
conditions. Accordingly, also an originally non-ionic detergent can
be used for providing nucleic acid complexes, if the detergent is
or becomes cationic during stabilisation, respectively complex
formation. Thus, besides cationic detergents comprising a
permanently charged head group also an originally ternary amine can
be used as cationic detergent if provided in an acidic environment
whereby the ternary amine incorporates a proton and become
positively charged.
[0133] According to one embodiment, an amino surfactant having the
following formula 2 is used as detergent in the stabilisation
composition which is or becomes cationic under the used
stabilisation conditions and thereby functions as cationic
detergent:
R1R2R3N(O)x (2)
wherein,
[0134] R1 and R2 each independently is H, C1--C20 alkyl residue,
C6--C26 aryl residue or C6--C26 aralkyl residue, preferably H,
C1--C6 alkyl residue, C6--C12 aryl residue or C6--C12 aralkyl
residue,
[0135] R3 is C1--C20 alkyl group, C6--C26 aryl residue or C6--C26
aralkyl residue,
[0136] X is an integer of 0 and 1.
[0137] According to one embodiment, x is 1 and R1 and R2 each
independently is C1--C6 alkyl, and R3 is C1-C20 alkyl. According to
a preferred embodiment, x is 0. According to one embodiment, said
amino surfactant is selected from the group consisting of
dodecylamine, N-methyldodecylamine, N,N-dimethyldodecylamine,
N,N-dimethyldodecylamine N oxide and 4-tetradecylaniline.
Preferably, said amino surfactant is comprised in a stabilisation
composition which additionally comprises at least one proton donor,
preferably an acid or acid salt to render a quarternary ammonium
cation. According to one embodiment, the stabilization composition
comprises at least one acid salt selected from the group consisting
of maleic acid, tartaric acid, citric acid, oxalic acid, carboxylic
acids and mineral acids. The total concentration of said acid salt
in the stabilization composition may preferably range from 0.01 M
to 1 M.
[0138] Complex samples that are stabilised as is described above
using a cationic detergent are a particular challenge for isolating
nucleic acids due to the additives in the stabilising solution and
the high protein content of the sample, in particular if the sample
is a blood sample or a sample derived from blood. The method of the
present invention overcomes these difficulties and allows the
isolation of RNA including small RNA (if desired) with good yield
and high purity from respectively stabilised samples and in
particular from complex biological samples such as whole blood and
blood products such as buffy coat, serum and/or plasma or tissue
samples, in particular organ tissue samples e.g. obtained from lung
or liver. Therefore, the method of the present invention is
particularly useful in the medical and in particular in the
diagnostic field.
[0139] According to one embodiment, the resuspended sample
comprising the nucleic acid, the at least one chaotropic agent, the
at least one chelating agent and optionally the protein-degrading
compound is put on hold between step c) and step d). Said holding
time prior to isolating the nucleic acid in step d) may have a
duration of more than 0.1 h, more than 0.25 h, more than 0.5 h,
more than 0.75 h, more than 1 h, more than 1.5 h, more than 2 h,
more than 2.5 h or more than 3 h hours and preferably lies in a
range selected from 0.25 h to 12 h, 0.5 h to 11 h, 0.75 h to 10 h,
1 h to 9 h, 1.25 h to 8.5 h, 1.5 h to 8 h, 1.75 h to 7.5 h, 1.25 h
to 7 hours, 1.5 h to 6.5 h, 1.75 h to 6 h and 2 h to 5.5 h.
[0140] As discussed above, the circumstance that samples are put on
hold between the resuspension in step c) and the actual nucleic
isolation step d) often occurs when processing a plurality of
samples using an automated system. As discussed above, the samples
are often manually prepared (e.g. by centrifuging the samples to
obtain the pellet comprising the complexes comprising the cationic
detergent and the nucleic acids and adding the resuspension
chemistry) for nucleic acid isolation. Afterwards, the prepared,
resuspended samples are placed into a robotic system for nucleic
acid isolation. Said robotic systems may also execute the digestion
step described above as they are often designed to perform heating
and/or agitation steps. The method according to the present
invention has particular advantages when processing a plurality of
samples, in particular when using an automated system.
[0141] Thus, according to one embodiment, a plurality of samples is
processed, wherein the holding time between step c) and step d)
differs at least between some of the resuspended samples. According
to this embodiment, a plurality of samples is processed according
to the present method up to step c). After resuspension in step c),
a portion of said plurality of samples is further processed
according to step d), while the remaining, resuspended samples are
put on hold. These resuspended samples that were put on hold are
then further processed according to step d), preferably after the
nucleic acids were isolated from the first portion of resuspended
samples.
[0142] Preferably, the plurality of samples is processed using an
automated system which is capable of processing magnetic particles.
Using magnetic particles to isolate nucleic acids from the
resuspended sample in step d) is beneficial because of the
simplified handling. Magnetic particles can be processed by the aid
of a magnetic field. Suitable and preferred magnetic particles are
described above. Here, different automated robotic systems exist in
the prior art that can be used in conjunction with the present
invention to process magnetic particles during nucleic acid
isolation in step d). According to one embodiment, magnetic
particles are collected at the bottom or the side of the reaction
vessel and the remaining liquid sample is removed from the reaction
vessel, leaving behind the collected magnetic particles to which
the nucleic acids are bound. Removal of the remaining sample can
occur by decantation or aspiration. Such systems are well known in
the prior art and thus need no detailed description here. In an
alternative system that is known for processing magnetic particles
the magnet which is usually covered by a cover or envelope plunges
into the reaction vessel to collect the magnetic particles. The
magnetic particles that carry the bound nucleic acids can then be
transferred for example into a new reaction vessel e.g. comprising
further processing solutions such as e.g. a washing solution. As
respective systems are well-known in the prior art and are also
commercially available (e.g. QIAsymphony; QIAGEN), they do not need
any detailed description here. In a further alternative automated
system that is known for processing magnetic particles, the sample
comprising the magnetic particles can be aspirated into a pipette
tip and the magnetic particles can be collected in the pipette tip
by applying a magnet e.g. to the side of the pipette tip. The
remaining sample can then be released from the pipette tip while
the collected magnet particles which carry the bound nucleic acids
remain due to the magnet in the pipette tip. The collected magnetic
particles can then be processed further. Such systems are also
well-known in the prior art and are also commercially available
(e.g. BioRobot EZ1, QIAGEN) and thus, do not need any detailed
description here.
[0143] The term "sample" is used herein in a broad sense and is
intended to include a variety of sources that contain nucleic
acids. The sample may be a biological sample but the term also
includes other, e.g. artificial samples which comprise nucleic
acids. Exemplary samples include, but are not limited to, body
fluids in general, whole blood; serum; plasma; red blood cells;
white blood cells; buffy coat; swabs, including but not limited to
buccal swabs, throat swabs, vaginal swabs, urethral swabs, cervical
swabs, throat swabs, rectal swabs, lesion swabs, abcess swabs,
nasopharyngeal swabs, and the like; urine; sputum; saliva; semen;
lymphatic fluid; liquor; amniotic fluid; cerebrospinal fluid;
peritoneal effusions; pleural effusions; fluid from cysts; synovial
fluid; vitreous humor; aqueous humor; bursa fluid; eye washes; eye
aspirates; plasma; serum; pulmonary lavage; lung aspirates; and
tissues, including but not limited to, liver, spleen, kidney, lung,
intestine, brain, heart, muscle, pancreas, cell cultures, as well
as lysates, extracts, or materials obtained from any cells and
microorganisms and viruses that may be present on or in a sample
and the like. Materials obtained from clinical or forensic settings
that contain nucleic acids are also within the intended meaning of
the term sample. Furthermore, the skilled artisan will appreciate
that lysates, extracts, or materials or portions thereof obtained
from any of the above exemplary samples are also within the scope
of the term sample. Preferably, the sample is a biological sample
derived from a human, animal, plant, bacteria or fungi. In
particular, the term "sample" refers to a nucleic acid containing
sample which also comprises proteins. Preferably, the sample is
selected from the group consisting of cells, tissue, bacteria,
virus and body fluids such as for example blood, blood products
such as buffy coat, plasma and serum, urine, liquor, sputum, stool,
CSF and sperm, epithelial swabs, biopsies, bone marrow samples and
tissue samples, preferably organ tissue samples such as lung and
liver. Preferably, the sample is selected from whole blood and
blood products such as buffy coat, serum or plasma.
[0144] The term "nucleic acid" or "nucleic acids" as used herein,
in particular refers to a polymer comprising ribonucleosides and/or
deoxyribonucleosides that are covalently bonded, typically by
phosphodiester linkages between subunits, but in some cases by
phosphorothioates, methylphosphonates, and the like. Nucleic acids
include, but are not limited to all types of DNA and/or RNA, e.g.
gDNA; circular DNA; circulating DNA; hnRNA; mRNA; noncoding RNA
(ncRNA), including but not limited to rRNA, tRNA, IncRNA (long non
coding RNA), lincRNA (long intergenic non coding RNA), miRNA (micro
RNA), siRNA (small interfering RNA), snoRNA (small nucleolar RNA),
snRNA (small nuclear RNA) and stRNA (small temporal RNA), piRNA
(piwi interacting RNA), tiRNA (transcription initiation RNA), PASR
(promoter associated RNA), CUT (cryptic unstable transcripts),
extracellular or circulating RNA; fragmented nucleic acid; nucleic
acid obtained from subcellular organelles such as mitochondria or
chloroplasts; and nucleic acid obtained from microorganisms,
parasites, or DNA or RNA viruses that may be present in a
biological sample. Synthetic nucleic acid sequences that may or may
not include nucleotide analogs that are added or "spiked" into a
biological sample are also within the scope of the invention. Small
RNA or the term small RNA species in particular refers to RNA
having a length of less than 500 nt, 400 nt, 300 nt or 100 nt and
includes but is not limited to miRNA, siRNA, other short
interfering nucleic acids, snoRNAs and the like. According to one
embodiment, the nucleic acid is RNA. The RNA may include small RNA
species.
[0145] As becomes apparent from the described examples of samples
that can be processed according to the method of the present
invention, a sample may comprise more than one type of nucleic
acid. Depending on the intended use, it may be desirous to isolate
all types of nucleic acids from a sample ((e.g. DNA and RNA) or
only certain types or a certain type of nucleic acid (e.g. only RNA
but not DNA or vice versa or DNA and RNA are supposed to be
obtained separately). All these variants are within the scope of
the present invention. Suitable methods for isolating either DNA or
RNA or both types of nucleic acids in parallel are known in the
prior art and are also described above.
[0146] The present invention also pertains to a method for
isolating nucleic acids from a sample, preferably a blood sample,
wherein the nucleic acids are isolated from a plurality of samples
and wherein variations in yield and quality of the nucleic acids
that are isolated from said plurality of samples which result from
that the plurality of samples prepared for isolation have diverging
holding times before the nucleic acids are isolated from the
prepared samples are thereby reduced that the samples prepared for
isolation comprise at least one chaotropic agent and at least one
chelating agent.
[0147] The sample is preferably stabilised by using a cationic
detergent which forms a complex with the nucleic acid contained in
the sample. Details with respect to the cationic detergent are
described above, it is referred to the above disclosure.
Preferably, the nucleic acid is RNA and the sample is or is derived
from a body fluid, preferably whole blood, serum or plasma, most
preferred whole blood. According to one embodiment, the nucleic
acids are isolated according to the method described above. It is
referred to the above disclosure which also applies here.
[0148] Furthermore, the present invention pertains to the use of a
chelating agent for preventing the formation of a precipitate that
interacts with the container wall of a sample comprising a
chaotropic agent and a nucleic acid. The sample is preferably
stabilised by using a cationic detergent which forms a complex with
the nucleic acid contained in the sample. Details with respect to
the cationic detergent are described above, it is referred to the
above disclosure. Preferably, the nucleic acid is RNA and the
sample is or is derived from a body fluid, preferably whole blood,
serum or plasma, most preferred whole blood. The advantages of a
respective use of a chaotropic agent and a chelating agent in
particular with respect to the increase in nucleic acid quality and
quantity due to the prevention of the precipitate formation and/or
adherence to the container wall were described in detail above.
Suitable and preferred embodiments of the chelating agent and
concentrations thereof, the chaotropic agent and concentrations
thereof, the cationic detergent, the nucleic acids and sample types
are described above. It is referred to the above disclosure which
also applies here.
[0149] This invention is not limited by the exemplary methods and
materials disclosed herein, and any methods and materials similar
or equivalent to those described herein can be used in the practice
or testing of embodiments of this invention. Numeric ranges are
inclusive of the numbers defining the range. The headings provided
herein are not limitations of the various aspects or embodiments of
this invention which can be read by reference to the specification
as a whole. The term "solution" as used herein, in particular
refers to a liquid composition, preferably an aqueous composition.
It may be a homogenous mixture of only one phase but it is also
within the scope of the present invention that a solution that is
used according to the present invention comprises solid components
such as e.g. precipitates. According to one embodiment, subject
matter described herein as comprising certain steps in the case of
methods or as comprising certain ingredients in the case of
compositions, solutions and/or buffers refers to subject matter
consisting of the respective steps or ingredients. It is preferred
to select and combine preferred embodiments described herein and
the specific subject-matter arising from a respective combination
of preferred embodiments also belongs to the present
disclosure.
EXAMPLES
[0150] The present invention is now illustrated by the following
non-limiting examples:
Example 1
[0151] 24 blood samples (2.5 ml) were collected per batch in
PAXgene Blood RNA Tubes (which comprise a cationic detergent as
stabilising agent). The samples were stabilized for 24 h at room
temperature and were processed with the QIAsymphony PAXgene Blood
RNA Kit, 2008 (QIAGEN) according to the manufacturer's
instructions.
[0152] QIAsymphony PAXgene Blood RNA Kit
[0153] In the QIAsymphony PAXgene Blood RNA protocol (prior art),
the stabilised samples are manually prepared in order to collect
and resuspend the pellet which comprises the complexes comprising
the cationic detergent and the nucleic acids. Said pellet is
obtained by centrifugation and the supernatant is decanted.
Afterwards, 300 .mu.l of the resuspension buffer BR1 (QIAGEN) was
added to the pellet and vortexed. The respectively manually
prepared samples were then loaded on the QIAsymphony robotic system
and the nucleic acids were isolated from the resuspended samples
according to the QIAsymphony script.
[0154] The first batch was directly processed after resuspension,
the second batch after 2 hours 5 minutes. Thus, the samples of the
second batch had a 2 hours 5 minutes longer holding time.
[0155] Modified Version Comprising the Addition of a Chaotropic
Agent During Resuspension
[0156] The QIAsymphony PAXgene Blood RNA protocol was modified by
adding a chaotropic agent to the resuspended sample in order to
preserve the RNA integrity. The blood samples were manually
prepared as described above. After the resuspension buffer BR1 was
added to the pellet and vortexed, 200 .mu.l of a further solution
(BR2, QIAGEN) was added which comprises a chaotropic salt (GITC).
The chaotropic salt was added to preserve the RNA integrity. The
samples were then processed according to two different versions.
According to version 1, the samples were directly loaded on the
QIAsymphony robot after the buffer BR2 was added. According to
version 2, the samples were vortexed after the addition of the
buffer BR2 and then loaded on the QIAsymphony robot. In the
QIAsymphony robotic system, the nucleic acids were then isolated
from the resuspended samples according to the QIAsymphony
script.
[0157] The quality of the isolated RNA was determined with the
Agilent Bioanalyzer and expressed in RIN values (RIN=RNA integrity
number).
[0158] Results
[0159] The results are shown in FIG. 1:
[0160] 1: QIAsymphony PAXgene Blood RNA--first batch
[0161] 2: QIAsymphony PAXgene Blood RNA--second batch
[0162] 3: QIAsymphony PAXgene Blood RNA modified (addition of
chaotropic agent)--second batch (no vortexing)
[0163] 4: QIAsymphony PAXgene Blood RNA modified (addition of
chaotropic agent)--second batch (vortexing)
[0164] FIG. 1 shows that the RNA integrity is excellent with the
first batch of the samples that were processed according to the
prior art protocol. However, the RNA integrity decreases in the
second batch which had a longer holding time between resuspension
of the sample and nucleic acid extraction. Thus, longer holding
times decrease the RNA integrity and hence the quality of the
RNA.
[0165] The modified versions, wherein a chaotropic salt is added to
the resuspended samples show no differences with respect to the RNA
quality between batch 1 and batch 2. Thus, the RNA integrity is
preserved even if the samples have a long holding time of two hours
and more.
Example 2
[0166] In Example 2, the QIAsymphony PAXgene Blood RNA protocol
described above and a modified version (wherein a chaotropic agent
is added during resuspension) was analysed with respect to the
nucleic acid yield. In said modified version 3 that was tested in
Example 2, the nucleic acid isolation was also performed on the
QIAsymphony according to the QIAsymphony PAXgene Blood RNA
protocol, however, using a modified binding buffer in order to
improve nucleic acid binding, in particular the binding of small
RNA. The modified binding buffer that was used in Example 2 instead
of the binding buffer QSB1 that is used in the QIAsymphony PAXgene
Blood RNA protocol, comprised more than 60% isopropanol and 0.2 M
sodium trichloroacetate. Respectively modified binding buffers to
achieve improved binding in particular of small nucleic acids and
corresponding nucleic acid isolation protocols are described in EP
10 000 432.4, herein incorporated by reference. The resuspension of
the sample was performed as described in Example 1 (modified
version) and hence, a chaotropic agent (GITC) was added in form of
buffer BR2 to preserve the RNA integrity.
[0167] For the respectively modified version 3, 3 batches were
tested. The first batch of samples was directly processed after
sample resuspension, the second batch had a holding time of 2 hours
5 minutes, the third batch had a holding time of 4 hours 10
minutes. As additional reference, samples were also processed with
the PAXgene Blood RNA Kit (a membrane based, single spin column
method) according to the manufacturers instructions. The results of
Example 2 are shown in FIG. 2:
[0168] 1: QIAsymphony PAXgene Blood RNA
[0169] 2: QIAsymphony PAXgene Blood RNA modified (addition of
chaotropic agent)--first batch
[0170] 3: QIAsymphony PAXgene Blood RNA modified (addition of
chaotropic agent)--second batch
[0171] 4: QIAsymphony PAXgene Blood RNA modified (addition of
chaotropic agent)--third batch
[0172] 5: PAXgene Blood RNA (IVD)
[0173] As can be derived from FIG. 2, the first batch of the
modified version achieves good yields which are also improved
compared to the prior art method. However, reduced yields are
observed for the 2.sup.nd and 3.sup.rd batch with the modified
version, wherein the chaotropic agent is added to the resuspended
sample to guarantee high RIN values (see Example 1 and FIG. 1). The
yield is reduced up to 20 to 30%. The reason for this loss in
nucleic acid yield is that a precipitate is formed during the
holding time which sticks tightly to the plastic wall of the
tube.
Example 3
[0174] In order to ensure both, a high RNA integrity and a high
nucleic acid yield, the protocol was modified according to the
teachings of the present invention. Thus, the pellet was
resuspended by adding a modified resuspension buffer, which
additionally comprised EDTA. For this purpose, 25 mM EDTA was added
to the resuspension buffer BR1 (QIAGEN) that is used for
resuspension in the prior art protocol. 280 .mu.l of this modified
resuspension buffer BR1 was added to the pellet that was obtained
from the PAXgene stabilised blood samples (see Example 1).
Furthermore, for resuspension 20 .mu.l proteinase K was added per
sample. The sample was resuspended by vortexing and 200 .mu.l of a
buffer comprising a chaotropic agent (BR2, QIAGEN--comprises>3 M
GITC) was added.
[0175] The resuspended samples were loaded on the QIAsymphony
robotic system and the automated nucleic acid extraction was
performed. In brief, the nucleic acid isolation protocol comprised
the following steps:
[0176] 1. Sample digestion
[0177] 40 .mu.l proteinase K was added to the resuspended sample
and incubated for 10 min under heating and shaking.
[0178] 2. DNA removal
[0179] Mag Attract G beads (QIAGEN) were added to the digested
sample to bind the DNA to the beads. The beads were than removed
from the sample.
[0180] 3. RNA binding
[0181] Mag Attract G beads (QIAGEN) were added and 1500 .mu.l of a
binding buffer comprising more than 65% isopropanol, sodium
trichloroacetate and a Tris buffer.
[0182] 4. Washing
[0183] Two washing steps were performed using the washing buffers
QSB1 and BR4 (QIAGEN).
[0184] 5. DNase and Proteinase K digest
[0185] The RNA was eluted and DNA traces were digested using DNase
I. Afterwards, a second proteinase K digest was performed (see EP
10 007 346.9, herein incorporated by reference).
[0186] 6. RNA Re-binding
[0187] 1400 .mu.l of the binding buffer (see above) was added.
[0188] 7. Washing
[0189] 4 final washing steps were performed (using the buffers
QSB1, QSW5 and BR4, all QIAGEN).
[0190] 8. Elution and heat denaturation
[0191] The RNA was eluted using 200 .mu.l BR5 (QIAGEN) and the
eluted nucleic acid was heat denatured for 10 min.
[0192] 24 blood samples were collected per batch in PAXgene Blood
RNA Tubes. This protocol according to the present invention was
compared to the modified version as described in example 2 (wherein
a chaotropic agent was added during resuspension to preserve the
RNA integrity but no EDTA). Three batches were tested in each
method. The first batch was directly processed after sample
resuspension, the second batch had a holding time of 2 hours 20
minutes hours, the third batch had a holding time of 4 hours 40
minutes hours. As additional reference, samples were processed with
the PAXgene Blood RNA kit (membrane based, single spin column
method).
[0193] The results are shown in FIGS. 3 to 6.
[0194] FIG. 3 shows the effect of the modified resuspension step
according to the present invention on the precipitate formation. On
the left hand side, the tubes of the 3.sup.rd batch are shown
wherein the samples were prepared according to the modified version
(see example 2), wherein a chaotropic agent is added during
resuspension (but no EDTA). As can be seen, a large precipitate is
formed which irreversibly sticks to the container walls and thus,
is lost for the subsequent nucleic acid isolation (=reduced yield,
see example 2). On the right hand side, the tubes of the 3.sup.rd
batch are shown wherein the samples were prepared according to the
method of the present invention, wherein EDTA is added during
resuspension in addition to the chaotropic agent. As can be seen,
the precipitate formation is substantially prevented with the
method according to the present invention.
[0195] FIG. 4 shows the overall RNA yield that is obtained with
different batches of the protocols under comparison:
[0196] 1: QIAsymphony PAXgene Blood RNA--first batch
[0197] 2: QIAsymphony PAXgene Blood RNA modified according to the
invention--first batch
[0198] 3: QIAsymphony PAXgene Blood RNA--second batch
[0199] 4: QIAsymphony PAXgene Blood RNA modified according to the
invention--second batch
[0200] 5: QIAsymphony PAXgene Blood RNA--third batch
[0201] 6: QIAsymphony PAXgene Blood RNA modified according to the
invention--third batch
[0202] 7: PAXgene Blood RNA (IVD)
[0203] FIG. 4 demonstrates that the samples that are processed
according to the method of the present invention achieve constant
high nucleic acid yields despite longer holding times between the
different batches. The nucleic acid yield is considerably
improved.
[0204] FIG. 5 shows the RNA integrity that is achieved with the
method according to the present invention. As can be seen, a high
RIN is obtained with all three batches. Thus, the integrity of the
RNA is preserved, despite long holding times.
[0205] FIG. 6 demonstrates the achieved yield of small RNAs:
[0206] 1: QIAsymphony PAXgene Blood RNA--first batch
[0207] 2: QIAsymphony PAXgene Blood RNA modified according to the
invention--first batch
[0208] 3: QIAsymphony PAXgene Blood RNA--second batch
[0209] 4: QIAsymphony PAXgene Blood RNA modified according to the
invention--second batch
[0210] 5: QIAsymphony PAXgene Blood RNA--third batch
[0211] 6: QIAsymphony PAXgene Blood RNA modified according to the
invention--third batch
[0212] 7: PAXgene Blood RNA (IVD)
[0213] FIG. 6 shows the mean C.sub.T obtained with the
miScript.RTM. Primer assay (hsa-miR 30b) when analysing the eluates
obtained with the different tested protocols. As can be seen, the
method achieves a good yield of small RNAs which is also
considerably improved compared to the prior art method.
Example 4
[0214] In example 4, the effects of the addition of EDTA during
resuspension on the RNA yield was further analysed. Optionally, a
protein-degrading compound (proteinase K) was added. For each test
series, 24 test tubes (PAXgene Blood RNA Tubes from QIAGEN) filled
with 2.5 ml whole human blood were obtained in duplicates from 12
individual donors and the nucleic acid containing pellet was
obtained. The supernatants were removed, and the pellets were
resuspended by vortexing in the fresuspension buffer BR1
(QIAGEN):
[0215] 280 .mu.l BR1 (QIAGEN), 20 .mu.l proteinase K solution
(QIAGEN) and 200 .mu.l of a GITC containing buffer (BR2,
QIAGEN);
[0216] 280 .mu.l BR1 (QIAGEN)+10 mM EDTA, 20 .mu.l proteinase K
solution (QIAGEN) and 200 .mu.l of a GITC containing buffer (BR2,
QIAGEN);
[0217] 280 .mu.l BR1 (QIAGEN)+25 mM EDTA, 20 .mu.l proteinase K
solution (QIAGEN) and 200 .mu.l of a GITC containing buffer (BR2,
QIAGEN);
[0218] 280 .mu.pl BR1 (QIAGEN)+50 mM EDTA, 20 .mu.l proteinase K
solution (QIAGEN) and 200 .mu.l of a GITC containing buffer (BR2,
QIAGEN);
[0219] 280 .mu.l BR1 (QIAGEN)+25 mM EDTA, 20 .mu.l proteinase K
solution (QIAGEN) and 200 .mu.l of a GITC containing buffer (BR2,
QIAGEN); or 300 .mu.l BR1 (QIAGEN)+25 mM (no proteinase K) and 200
.mu.l of a GITC containing buffer (BR2, QIAGEN).
[0220] The samples were processed according to the protocol
described in Example 3.
[0221] FIG. 7 shows the mean total RNA yield. For samples
resuspended in buffer BR1 with proteinase K and the chaotropic
agent but no EDTA, the RNA yield achieved from batch 1 samples
(with short holding time) was higher than for batch 2 samples (with
extended holding time). Samples that were resuspended using a
chaotropic agent, proteinase K and the chelating agent EDTA
generally yielded more RNA as can be seen from the nucleic acid
yields that are obtained with the first batch. Thus, the RNA yield
was generally improved. Furthermore, the RNA yield that is obtained
from the second batch of samples after an extended holding time is
comparable or--at higher EDTA concentrations (25 mM and 50
mM)--even better than the RNA yield that is obtained with the first
batch. Similar results are achieved if the proteinase K is omitted
during resuspension. Thus, the beneficial effect on the RNA yield
is attributable to the addition of the chelating agent.
Example 5
[0222] As explained above, the resuspended samples form
precipitates during longer holding times, in particular if a
chaotropic agent is added during resuspension. Precipitated
aggregates remain stuck to the test tube after RNA-processing and
are therefore not included in the purification procedure. As a
consequence, blood samples of later batches show more pronounced
precipitation than samples from earlier batches. Example 5 shows
that the precipitate formation and adherence to the container wall
that reduces the RNA yield (see above) occurs irrespective of the
container material and thus in glass tubes as well as in plastic
tubes.
[0223] Samples of stabilized whole human blood (using the PAXgene
stabilisation chemistry) were processed in glass or plastic tubes.
The stabilized samples were centrifuged, the supernatants were
removed, and the pellets were resuspended by vortexing in a mixture
of 300 .mu.l buffer BR1 and 200 .mu.l buffer BR2. Furthermore, the
resuspension protocol according to the present invention was
tested, wherein additionally 25 mM EDTA was added during
resuspension.
[0224] The resuspended samples were left aside for 4 hours. Then,
the supernatants were removed and the precipitates were documented
in both glass- and plastic-test tubes.
[0225] The results are shown in FIG. 8A and FIG. 8B. For both
materials tested, bulk precipitates were found stuck at the test
tube bottom for the samples that were resuspended without EDTA (see
FIG. 8A), representing lost material that will not be included in
the subsequent RNA isolation procedure and thus results in reduced
nucleic acid yields. Samples that were resuspended according to the
method according to the present invention, wherein accordingly,
EDTA was additionally included during resuspension, no precipitates
were found even after a holding time of 4 hours.
* * * * *